Chen P, Nirula A, Heller B, et al; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2020. doi: 10.1056/NEJMoa2029849. [Epub ahead of print].
ClinicalTrials.gov. A Study of LY3819253 (LY-CoV555) in preventing SARS-CoV-2 infection and COVID-19 in nursing home residents and staff (BLAZE-2). Updated November 10, 2020. Accessed December 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04497987
ClinicalTrials.gov. ACTIV-3: Therapeutics for inpatients with COVID-19 (TICO). Updated November 9, 2020. Accessed December 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04501978
ClinicalTrials.gov. ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19. Updated December 14, 2020. Accessed December 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04583956
ClinicalTrials.gov. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19. Updated December 14, 2020. Accessed December 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04583969
ClinicalTrials.gov. Immune Modulators for Treating COVID-19 (ACTIV-1 IM). Updated December 15, 2020. Accessed December 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04593940
ClinicalTrials.gov. Safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for the treatment of ambulatory adult and pediatric patients with COVID-19. Updated December 15, 2020. Accessed December 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04425629
Côté A, Ternacle J, Pibarot P. Early prediction of the risk of severe coronavirus disease 2019: A key step in therapeutic decision making. EBioMedicine. 2020;59:102948.
Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9-14.
European Centre for Disease Prevention and Control website. High-risk groups for COVID-19. Published 2020. Accessed December 16, 2020. https://www.ecdc.europa.eu/en/covid-19/high-risk-groups
Jones BE, Brown-Augsburger PL, Corbett KS, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv [Preprint]. 2020 Oct 1:2020.09.30.318972. [Epub ahead of print]
Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1.
Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14:152-157.
Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324:131–132.
Regeneron. Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients. News release. September 29, 2020. Accessed December 16, 2020. https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and
Renn A, Fu Y, Hu X, et al. Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci. 2020;41:815-829.
Sun A, Benet LZ. Late-stage failures of monoclonal antibody drugs: a retrospective case study analysis. Pharmacology. 2020;105:145-163.
US Food and Drug Administration website. Bamlanivimab Emergency Use Authorization. Published November 10, 2020. Accessed December 16, 2020. https://www.fda.gov/media/143602/download
US Food and Drug Administration website. Casirivimab and Imdevimab Emergency Use Authorization. Published November 21, 2020. Accessed December 16, 2020. https://www.fda.gov/media/143891/download
Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. J Clin Virol. 2020;127:104358.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

John Whyte, MD, MPH

Chief Medical Officer
WebMD
New York, New York

Disclosures

Disclosure: John Whyte, MD, MPH, has disclosed the following relevant financial relationships:
Other: Chief Medical Officer of WebMD

Peter Chen, MD

Professor of Medicine and Biomedical Sciences
Director
Division of Pulmonary and Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Disclosures

Disclosure: Peter Chen, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly

Editors

Maria B. Uravich, BSc

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Maria B. Uravich, BSc, has disclosed no relevant financial relationships.

Julia Muino, MA

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Julia Muino, MA, has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

New Treatment Options for High-Risk COVID-19 Patients With Mild to Moderate Disease

Authors: John Whyte, MD, MPH; Peter Chen, MD
CME / ABIM MOC Released: 11/30/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/30/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, diabetologists, endocrinologists, and ID/HIV specialists.

The goal of this activity is to review the role of neutralizing antibodies (NAbs) in the development of the immune response and evaluate their role in the treatment of coronavirus disease 2019 (COVID-19).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Distinguishing characteristics of treatment with NAbs therapy vs other modalities of COVID-19 treatment
- Safety data for NAbs under study for the treatment of COVID-19
- Efficacy data for NAbs under study for the treatment of COVID-19
Demonstrate greater confidence in their ability to
- Identify patient populations who are most likely to benefit from treatment with NAbs

Disclosures

Faculty

John Whyte, MD, MPH

Chief Medical Officer
WebMD
New York, New York

Disclosures

Disclosure: John Whyte, MD, MPH, has disclosed the following relevant financial relationships:
Other: Chief Medical Officer of WebMD

Peter Chen, MD

Professor of Medicine and Biomedical Sciences
Director
Division of Pulmonary and Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Disclosures

Disclosure: Peter Chen, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly

Editors

Maria B. Uravich, BSc

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Maria B. Uravich, BSc, has disclosed no relevant financial relationships.

Julia Muino, MA

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Julia Muino, MA, has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC

New Treatment Options for High-Risk COVID-19 Patients With Mild to Moderate Disease

Authors: John Whyte, MD, MPH; Peter Chen, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/30/2020

Valid for credit through: 11/30/2021, 11:59 PM EST

processing....

Pre-Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

John Whyte, MD, MPH

Peter Chen, MD

Editors

Maria B. Uravich, BSc

Julia Muino, MA

CME Reviewer

Robert Morris, PharmD

Peer Reviewer

CME / ABIM MOC

New Treatment Options for High-Risk COVID-19 Patients With Mild to Moderate Disease

Target Audience and Goal Statement

Disclosures

Faculty

John Whyte, MD, MPH

Peter Chen, MD

Editors

Maria B. Uravich, BSc

Julia Muino, MA

CME Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

New Treatment Options for High-Risk COVID-19 Patients With Mild to Moderate Disease

Pre-Assessment Survey